BioTuesdays

Author - Sydney Stewart

Cerus

BTIG hikes Cerus to buy with $7 PT

BTIG upgraded Cerus (NASDAQ:CERS) to “buy” from “neutral” with a $7 price target. The stock closed at $4.28 on Nov. 12. Cerus is focused on developing the INTERCEPT blood system to enhance blood safety through reducing...

Hepion Pharmaceuticals

Roth starts Hepion Pharma at buy; PT $9

Roth Capital Partners launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and $9 price target. The stock closed at $2.95 on Nov. 6. “Hepion brings a laser focus on liver disease, combined with...

Ventripoint names Justin Leushner as CEO

Ventripoint Diagnostics (TSXV:VPT; OTC:VPTDF) appointed Justin Leushner as CEO, replacing Dr. George Adams, who was elected chairman of the board. Mr. Leushner, who was named president of Ventripoint in September, has a...

Zealand Pharma

Zealand Pharma acquires Encycle Therapeutics

Zealand Pharma (NASDAQ:ZEAL) of Denmark has acquired Encycle Therapeutics, a closely-held biotech company in Toronto, exploiting a unique platform technology that enables the rapid synthesis of macrocyclic peptides...

Senseonics

Stifel starts Senseonics at buy; PT $2

Stifel initiated coverage of Senseonics Holdings (NYSE American:SENS) with a “buy” rating and $2 price target. The stock closed at 95 cents on Oct. 22. Senseonics is an emerging company with a long-duration, implantable...

Subscribe

Sign up to our weekly BioTuesdays newsletter.